✦ LIBER ✦

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective

✍ Scribed by Eckstein, Niels; Röper, Lea; Haas, Bodo; Potthast, Henrike; Hermes, Ulrike; Unkrig, Christoph; Naumann-Winter, Frauke; Enzmann, Harald

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatotoxicity of Tyrosine Kinase Inhibi

✍ Shah, Rashmi R.; Morganroth, Joel; Shah, Devron R. 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 322 KB

Phase I clinical and pharmacological eva

✍ Cristiana Sessa; Lucia Viganò; Giacomo Grasselli; Josè Trigo; Irene Marimon; Ann 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 450 KB

Second-generation irreversible epidermal

✍ Sai-Hong Ignatius Ou 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 556 KB

Effect of the tyrosine kinase inhibitors

✍ Agostino, N. M.; Chinchilli, V. M.; Lynch, C. J.; Koszyk-Szewczyk, A.; Gingrich, 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 151 KB

Clinical Significance of Heterogeneity i

✍ Lee, Youngjoo; Kim, Hyae Young; Lee, Soo-Hyun; Lim, Kun Young; Lee, Geon Kook; Y 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 764 KB

Drug resistance and BCR-ABL kinase domai

✍ Soverini, Simona; De Benedittis, Caterina; Papayannidis, Cristina; Paolini, Stef 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB